Moalife Transfers Muscle Disease Treatment Technology to US Company

Moa Life Plus announced on the 2nd that it has transferred the technology for two muscle disease treatment candidate substances to the U.S. medical aesthetic specialized biotech company 'Elevai Labs.'

Both drugs are oral new drug candidates developed based on Moa Life's probiotic engineering platform technology, MucoMax. BLS-M22 was developed targeting myostatin, a representative muscle degradation signaling molecule. It has completed Phase 1 clinical trials in Korea as a treatment for Duchenne Muscular Dystrophy (DMD). Additionally, BLS-M32 was developed as a treatment for sarcopenia by dual targeting myostatin and activin-A. It is currently in the preclinical stage.

Elevai Labs holds exclusive rights for development and commercialization of BLS-M22 and BLS-M32 worldwide except Korea. Moa Life will receive milestone payments based on clinical development and sales milestones of the two candidates. They will also receive royalties on net sales generated by Elevai Labs, its affiliates, or sublicensees. The total amount Moa Life can receive from development and sales milestones is $130 million (approximately 180 billion KRW).

Elevai Labs is a medical aesthetic biotech company based on its independently developed skin regeneration exosome platform technology (PREx, Precision Regenerative Exosome Technology™). Currently, it has developed and sells skin regeneration products ELEVAI Empower™ and daily skin health enhancement cosmetics ELEVAI enfinity™ using exosomes containing stem cell growth factors.

Elevai Labs’ Chief Medical Officer (CMO) stated, "Myostatin is a validated target with potential for increasing muscle mass and strength and is currently being tested in combination with GLP-1 obesity treatments. We believe Moa Life’s licensed drugs have differentiation in oral administration compared to other myostatin strategies being developed alongside obesity treatments." He added, "The approach inducing anti-myostatin antibody production through mucosal immunity could effectively address the issues of currently marketed GLP-1 class obesity treatments."

Moa Life’s Business Development (BD) executive explained, "This license agreement has become an opportunity to have our platform technology recognized overseas. By starting clinical development in the U.S., we have taken a step closer to the commercialization of treatments for muscle loss diseases."

This content was produced with the assistance of AI translation services.